Physician profile
Casey A Long
NPI 1609284751
$9,037.39
in general payments reported to CMS, 2019-2025
57 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $794 · 2021: $1,818 · 2022: $2,130 · 2023: $1,271 · 2024: $1,083 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $716.79 | 2019-2024 | Relistor, Xifaxan, Cycloset |
| Abbott Laboratories | $713.66 | 2019-2023 | Freestyle Libre 2 |
| Abbvie INC. | $675.62 | 2021-2025 | |
| Amgen INC. | $628.17 | 2019-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $585.34 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $455.76 | 2019-2024 | |
| Astellas Pharma US INC | $377.37 | 2020-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $375.43 | 2019-2025 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $364.19 | 2021-2024 | Spravato |
| Glaxosmithkline, LLC. | $361.12 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $291.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $232.35 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $229.91 | 2020-2025 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $193.55 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $179.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.